Belite Bio

Research only

BLTE · Tracked drugs and regulatory events

Tracked programs

1 program

Stargardt disease type 1

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releasebelitebio.gcs-web.com

Sponsor reports NDA acceptance for tinlarebant in Stargardt disease and a February 12, 2027 FDA target.

Sponsor describes tinlarebant as an oral small-molecule RBP4 antagonist.

Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.